Associated Papers
Unveiling the clinical impact of plasma-only mutations in non-small cell lung cancer: a Korean multicenter experience.
Lee JW et al.
Translational Lung Cancer Research, 2025
41367553 (PubMed )
Supplement: tlcr-14-11-4973-supplementary.pdf
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Yonesaka K et al.
Clinical Lung Cancer, 2023
DeteX: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research.
Cui Y et al.
Frontiers in Genetics, 2022
36685970 (PubMed )
Supplement: Table5.xlsx › Sheet1
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
34788622 (PubMed )
Supplement: NIHMS1757901-supplement-2.xlsx › SNVs_indels
Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations.
Kim IA et al.
Cancers, 2021
34298845 (PubMed )
Supplement: cancers-13-03632-s001.zip › cancers-1262449-supplementary.pdf
Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients.
Marin E et al.
Diagnostics (basel, Switzerland), 2020
33153192 (PubMed )
Supplement: diagnostics-10-00902-s001.pdf
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.
Pleasance E et al.
Nature Cancer, 2020
35121966 (PubMed )
Supplement: 43018_2020_50_MOESM3_ESM.xlsx › Supplementary_Table_5
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Select a paper to view details